Reply to thread

If you actually saw the internal documents you would know that the CEO and his cronies from Retrophin were the only ones involved in this pricing decision.  The commercial leadership found out what the price was the morning of the "launch meeting" for the sales team.  Since then Turing has slowly "melted" away based on the high percentage of patients in government programs (where price remains 1 penny a pill) and most commercial payers rejecting claims that are then covered by the patient assistance program.  A path that would have been predictable if the commercial leaders in sales and marketing would have been able to use their experience to inform the pricing decision.  Oh well....